Toni Choueiri, MD· @DrChoueiri · X·· 1 天前评分70
正文 · 机器翻译
@Uro_Oncologist 作了精彩报告，介绍了 #Keynote-B15 的 HRQoL 结果。
围手术期 EV-P 并未伴随总体 HRQoL 或膀胱切除术特异性 HRQoL 出现具有临床意义的损害！
#ESMO26 #Day2 @myESMO @OncoAlert
84 浏览 · 4 赞 · 3 转发 · 0 回复
会议摘要
4734O按 Proffered paper 1: Genitourinary tumour, renal and urothelial 对上
ctDNA analysis of the Phase 3 KEYNOTE-B15 trial: neoadjuvant and adjuvant (neoadj-adj) enfortumab vedotin (EV) + pembrolizumab (pembro) for participants (pts) with muscle-invasive bladder cancer (MIBC) who are eligible for cisplatin
https://esmocongress.esmo.orgNCT04700124NCT04700124按 - **标题 / Title：** Perioperative Enfortumab Vedotin (EV) Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Chemotherapy for Cisplatin-Eligible Muscle Invasive Bladder Cancer (MIBC) (MK-3475-B15/ KEYNOTE-B15 / EV-304) 对上
- **标题 / Title：** Perioperative Enfortumab Vedotin (EV) Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Chemotherapy for Cisplatin-Eligible Muscle Invasive Bladder Cancer (MIBC) (MK-3475-B15/ KEYNOTE-B15 / EV-304)
https://esmocongress.esmo.org来源：Toni Choueiri, MD · x.com